KORU Medical Systems, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KORU Medical Systems, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.13M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $33.65M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $28.52M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $27.90M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $23.49M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $24.18M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $23.16M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $17.35M | Mar 4, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Feb 28, 2017 | $12.29M | May 5, 2017 |
| FY2017 | Feb 29, 2016 | $12.25M | May 5, 2017 |
| FY2015 | Feb 28, 2015 | $11.24M | May 13, 2016 |
| FY2015 | Feb 28, 2014 | $8.70M | May 8, 2015 |
| FY2013 | Feb 28, 2013 | $7.76M | May 29, 2014 |
| FY2012 | Feb 29, 2012 | $6.39M | May 29, 2013 |
| FY2011 | Feb 28, 2011 | $4.92M | May 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.60M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $21.33M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $16.71M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $15.37M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $13.77M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $14.94M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $14.85M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $10.81M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $8.14M | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | $7.57M | May 5, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.64M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($6.07M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($13.74M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($8.66M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($4.56M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($1.21M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $564.3K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $910.6K | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $905.0K | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | ($535.0K) | May 5, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.97M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($6.45M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($10.27M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($10.78M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($7.03M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($1.25M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $585.7K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.16M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $1.24M | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | ($736.3K) | May 5, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.39M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.26M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $5.74M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.96M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.47M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $1.30M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $740.5K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $241.1K | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $50.6K | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | $237.5K | May 5, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.38M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $21.63M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $20.37M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $20.61M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $17.86M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $12.03M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $9.77M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $8.20M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $6.59M | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | $7.77M | May 5, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $462.4K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($319.7K) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($4.89M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($5.40M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($4.32M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($743.3K) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $320.6K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.48M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $899.9K | Mar 5, 2019 |
| FY2015 | Feb 28, 2015 | $826.1K | May 8, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Feb 28, 2017 | $203.1K | May 5, 2017 |
| FY2017 | Feb 29, 2016 | $121.8K | May 5, 2017 |
| FY2015 | Feb 28, 2015 | $591.4K | May 13, 2016 |
| FY2015 | Feb 28, 2014 | $188.7K | May 8, 2015 |
| FY2013 | Feb 28, 2013 | $563.6K | May 29, 2014 |
| FY2012 | Feb 29, 2012 | $236.2K | May 29, 2013 |
| FY2011 | Feb 28, 2011 | $200.5K | May 29, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.20M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $27.22M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $28.46M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $42.33M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $41.29M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $39.92M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $13.88M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $10.55M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $9.28M | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | $8.17M | May 5, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.15M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.40M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $8.11M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $11.01M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $4.79M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $3.76M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $2.65M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.58M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $1.61M | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | $1.49M | May 5, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.05M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.81M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $20.35M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $31.33M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $36.50M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $36.16M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $11.24M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $8.96M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $7.67M | Mar 4, 2020 |
| FY2018 | Feb 28, 2017 | $6.68M | Mar 5, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.02M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($29.38M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($23.31M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($9.57M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($910.1K) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $3.65M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $4.86M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $4.30M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $3.39M | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | $2.48M | May 5, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.87M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $9.58M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $11.48M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $17.41M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $25.33M | Mar 8, 2023 |
| FY2022 | Dec 31, 2020 | $27.32M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $5.87M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $3.74M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $3.97M | Mar 4, 2020 |
| FY2018 | Feb 28, 2017 | $3.31M | Mar 5, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Feb 28, 2013 | $439.3K | May 29, 2013 |
| FY2012 | Feb 29, 2012 | $482.8K | May 29, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | 0 | May 5, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | 0 | May 5, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.37M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 45.96M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 45.67M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 45.44M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 44.62M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 43.26M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 39.50M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 38.20M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | 37.99M | Mar 5, 2019 |
| FY2017 | Feb 28, 2017 | 37.82M | May 5, 2017 |